Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
After slump this ASX share may be an opportunity
Lower than expected guidance led to a sell-off.
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,133.40 | 18.80 | -0.21% |
| CAC 40 | 8,055.51 | 105.33 | 1.32% |
| DAX 40 | 23,959.99 | 390.03 | 1.65% |
| Dow JONES (US) | 47,368.63 | 381.53 | 0.81% |
| FTSE 100 | 9,787.15 | 104.58 | 1.08% |
| HKSE | 26,649.06 | 163.16 | 0.62% |
| NASDAQ | 23,527.17 | 522.64 | 2.27% |
| Nikkei 225 | 51,440.43 | 528.67 | 1.04% |
| NZX 50 Index | 13,591.01 | 26.47 | -0.19% |
| S&P 500 | 6,832.43 | 103.63 | 1.54% |
| S&P/ASX 200 | 8,856.20 | 19.40 | -0.22% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |